Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Pursuant to 35 U.S.C. §287(a), Captisol® is covered by or for use under one or more of the U.S. patents listed below and their foreign counterparts. Other patents pending.
8,049,003, 8,410,077, 8,829,182, 8,846,901, 9,200,088, 9,493,582, 9,750,822, 10,040,872, 10,117,951, 10,202,468, 10,323,103, and 10,800,861.
